Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder [11]

Journal of Clinical Psychopharmacology

Volumn 26, Issue 4, 2006, Pages 444-446

  Anagnostou, Evdokia ^a   Esposito, Katherine ^a   Soorya, Latha ^a   Chaplin, William ^b   Wasserman, Stacey ^a   Hollander, Eric ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; FLUOXETINE; GLUTAMATE DECARBOXYLASE 67; PLACEBO; REELIN; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROATE SEMISODIUM;

AGGRESSION; ASIAN; ASPERGER SYNDROME; AUTISM; CAUCASIAN; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEVELOPMENTAL DISORDER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; HISPANIC; HUMAN; IRRITABILITY; LETTER; MALE; NEGRO; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; RATING SCALE; SIDE EFFECT; STATISTICAL ANALYSIS; WECHSLER INTELLIGENCE SCALE; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIMANIC AGENTS; AUTISTIC DISORDER; CHILD; DOUBLE-BLIND METHOD; FLUOXETINE; HUMANS; IRRITABLE MOOD; PLACEBOS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 33746929827     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000227703.72117.bc     Document Type: Letter

References (14)

1. Hollander E, Dolgoff-Kaspar R, Cartwright C, et al. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry. 2001;62:530-534.
2. Duggal HS, Pathak PC, Coleman CC. Treating selective serotonin reuptake inhibitor-induced behavioral activation with valproate. J Child Adolesc Psychopharmacol. 2003;13: 113-114.
3. Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003;28:1186-1197.
4. Costa E, Grayson DR, Guidotti A. Epigenetic downregulation of GABAergic function in schizophrenia: potential for pharmacological intervention? Mol Interv. 2003;3:220-229.
5. Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005;30:582-589.
6. McDougle CJ. Current and emerging therapeutics of autistic disorder and related pervasive developmental disorders. In: Davis KL, Charney D, Coyle JT, et al, eds. Neuropsychopharmachology. Philadelphia, PA: Lippincott Williams and Wilkins; 2002:566-576.
7. Hollander E, Soorya L, Wasserman S, et al. Divalproex sodium vs. placebo in the treatment of repetitive behaviors in autism spectrum disorder. Int J Psychopharmacol. 2005;15:1-5.
8. Coccaro E, Harvey P, Kupsaw L, et al. Development of neuropharmacologically based behavioral assessments of impulsive aggressive behavior. J Neuropsychiatry Clin Neurosci. 1991;3:S44-S51.
9. Londorg PD, Ward T, Smith MD, et al. Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression. J Affect Disord. 2000;61:73-79.
10. Morales M, Bloom FE. The 5-HT3 receptor is present in different subpopulations of gabaergic neurons in the rat telencephalon. J Neurosci. 1997;17:3157-3167.
11. Barnes JM, Barnes NM, Costall B, et al. 5-HT3 receptors mediate inhibition of acetylcholine release in cortical tissue. Nature. 1989;338: 762-763.
12. Eisensamer B, Rammes G, Gimpl G, et al. Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor. Mol Psychiatry. 2003;8:994-1007.
13. Palvimaki EP, Roth BL, Majasuo H, et al. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor. Psychopharmacology.1996;126:234-240.
14. Kong EKC, Peng L, Chen Y, et al. Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration. Neurochem Res. 2002;27:113-120.